Telekom Srbija Raises €1.95 Billion Through Landmark Eurobond Transaction, Attracting Record Demand from Global Investors
12.5.2026 13:09:00 EEST | Business Wire | Press release
Telekom Srbija has successfully completed its second international corporate bond issuance, raising approximately €1.95 billion through a multi-tranche offering of senior unsecured notes denominated in U.S. dollars and euros.
The transaction generated exceptional investor interest, attracting total demand of USD 13.87 billion from approximately 300 leading international institutional investors, making it the largest corporate bond issuance ever executed in the Southeast / Central and Eastern Europe region, as well as one of the most heavily oversubscribed corporate transactions across emerging markets globally during 2025 and 2026.
The issuance attracted participation from many of the world’s most prominent pension funds, insurance companies, sovereign-affiliated investors, and global asset managers, with several top-tier international institutions investing in the region for the first time through Telekom Srbija’s offering.
The transaction was led by a consortium of leading international financial institutions, including BNP Paribas, Bank of America, Citi, Deutsche Bank, Eurobank, JPMorgan, OTP Bank, Raiffeisen Bank International, and UniCredit.
“Telekom Srbija’s transaction represents a landmark moment not only for the Company, but also for the broader regional capital market,” said Vladimir Lučić, Chief Executive Officer of Telekom Srbija.
“Reaching USD 13.87 billion in demand, with participation from approximately 300 global institutional investors — including some of the world’s most prominent pension and insurance funds — represents a strong endorsement of our long-term strategy, operational performance, and financial discipline. Telekom Srbija is increasingly being recognized not merely as a regional story, but as a credible international issuer with strong growth fundamentals and a clear path toward achieving an investment-grade credit rating.”
Pricing achieved across all tranches represented a significant improvement compared to the Company’s inaugural eurobond issuance, supported by Telekom Srbija’s strengthened credit profile, stable financial performance, and the high quality of investor demand.
The issuance follows a period of record operational and financial performance for Telekom Srbija. During 2025, the Company generated revenues of €2.3 billion and adjusted EBITDA of €1.3 billion, further solidifying its position as one of the leading telecommunications and digital infrastructure operators in Southeast Europe.
The transaction will enable Telekom Srbija to refinance existing debt under more favorable terms, extend its debt maturity profile across multiple currencies and maturities, and further optimize its capital structure without increasing overall indebtedness.
Investor participation in the offering positions Telekom Srbija among the more established emerging market issuers and significantly broadens the international investor base for future corporate issuances from the region.
The successful transaction is also expected to further increase the visibility of Serbian and regional capital markets among global institutional investors, while strengthening international confidence in Southeast Europe as a growing investment destination.
Telekom Srbija’s credit profile is supported by ratings from Moody’s, Fitch Ratings, and S&P Global Ratings. The Company also strategically aligned the timing of its latest Fitch rating upgrade immediately prior to the execution of the transaction, further reinforcing investor confidence and market positioning during a period of heightened global market uncertainty. This was further supported by the recently secured financing backed by the Export-Import Bank of the United States (EXIM Bank), intended to support the implementation of Telekom Srbija’s national 5G network development strategy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260512937684/en/
Contacts
Press Contact -
Ivana Bajović
ivanabajo@telekom.rs
+381 64 650 7300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom